サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：乳がん診断薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1348009

乳がん診断薬の世界市場-2023年～2030年

Global Breast Cancer Diagnostics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
乳がん診断薬の世界市場-2023年～2030年
出版日: 2023年09月11日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界保健機関（WHO）によると、乳がんは世界的に最も多く診断されるがんです。診断登録された乳がん症例数は、2020年の約230万人から増加し、2040年には300万人を超えると推定されています。浸潤性乳管がんは乳がんの中で最も一般的なタイプで、乳腺から始まり近隣の組織に転移します。10人の乳がん患者のうち、7～8人が浸潤性乳管がんです。

加齢は、女性における乳がんの最も一般的な原因の一つです。米国がん協会によると、2022年2月には、45歳未満の女性の8人に1人、55歳以上では3人に2人が乳がんにかかります。

ダイナミクス

診断技術の進歩

乳がん検診の進歩は、従来のマンモグラフィと比較してより良い結果をもたらします。人工知能とディープラーニングの統合により、乳がん検診はより正確で信頼性の高いものになります。機械学習と診断技術の統合は、乳がん患者のより正確な治療結果につながります。

例えば、2022年1月、デューク大学の研究者らは、マンモグラフィ検査でがんの可能性がある病変を分析し、患者が侵襲的な生検を受けるべきかどうかを判断する人工知能（AI）プラットフォームを作成しました。このAIは、マンモグラフィ画像の読み方のトレーニングに使用できる疑わしい病変を検出するのに役立ち、医師の医療判断を助けることができます。さらに、このAI技術は賢明な決断を下すために使われる可能性があります。

さらに2023年2月には、FathomX Pte Ltd.がAIとディープラーニングを利用したマンモグラフィを発売し、早期乳がん診断のための研究開発を行っています。マンモグラフィによる乳がん検診では、同社独自のAI技術により、X線画像からがん組織の兆候をより迅速かつ正確に検出することが可能になります。

さらに、乳がんの有病率、早期診断の必要性、製品の承認は、今後一定期間の市場を牽引するいくつかの要因です。

偽陽性結果

偽陽性の結果は、年齢が若い女性、乳房の密度が高い女性、乳房生検を受けたことのある女性、家族に乳がん患者がいる女性、エストロゲンを服用している女性に多く見られます。10年間に毎年マンモグラフィを受ける女性の約半数は、どこかの時点で偽陽性を示すでしょう。過去の既往歴により、偽陽性となる確率は約半分に減少します。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 診断技術の進歩
    • 抑制要因
      • 偽陽性
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 疫学
  • 米国・欧州主要5ヶ国 (5EU)・日本、中国・インドにおける乳がん検査実施数（2022年～2030年）
  • DMIの見解

第6章 COVID-19分析

第7章 がんタイプ別

  • 浸潤性小葉乳がん
  • 非浸潤性乳管がん（DCIS）
  • トリプルネガティブ乳がん
  • 炎症性乳がん
  • その他

第8章 検査タイプ別

  • 乳房臨床検査
  • 画像検査
    • MRI検査
    • 超音波検査
    • PET
    • その他
  • 血液検査
  • 生検
      • 摘出生検
      • 切開生検
      • コア生検
      • 細針吸引（FNA）生検
      • その他
  • その他

第9章 転移状態別

  • 局所
  • 近位
  • 遠位

第10章 ステージ別

  • ステージi
  • ステージII
  • ステージIII
  • ステージIV

第11章 エンドユーザー別

  • 病院・クリニック
  • がん診断センター
  • がん研究機関
  • 医療研究センター・研究所
  • 外来手術センター
  • その他

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第13章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第14章 企業プロファイル

  • Siemens Healthineers AG
    • 企業概要
    • 製品タイプのポートフォリオと説明
    • 財務概要
    • 主な動向
  • Kheiron Medical Technologies
  • Bio-Rad Laboratories
  • Hologic, Inc.
  • Quest Diagnostics Incorporated
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Illumina, Inc.
  • Metaltronica SpA
  • Carestream Health

第15章 付録

目次
Product Code: CD2142

Overview

According to the World Health Organization, breast cancer is the most commonly diagnosed type of cancer globally. The number of registered diagnostic breast cancer cases ase count has been estimated to climb from about 2.3 million new diagnoses in 2020 and is expected to more than 3 million in 2040. Invasive ductal carcinoma is the most common type of breast cancer, which starts in the mammary glands and spreads to nearby tissue. For every 10 breast cancer cases, 7 to 8 are invasive ductal carcinoma.

Aging is one of the most prevalent causes of breast cancer in women. According to the American Cancer Society, in February 2022, 1 out of 8 women younger than 45 years, 2 out of 3 in 55 years or older.

Dynamics

Advancements in diagnostic technologies

Advancements in breast cancer screening provide better outcomes when compared to conventional mammography. Integrating Artificial intelligence and deep learning makes breast cancer screening more accurate and reliable. Integration of machine learning with diagnostic techniques lead to more accurate treatment outcomes in breast cancer patients.

For instance, in January 2022, Duke University researchers created an Artificial Intelligence (AI) platform to analyze potentially cancerous lesions in mammography scans and determine whether patients should receive invasive biopsies. This AI helped to detect suspicious lesions that could be used to train students on how to read mammography images and can help physicians make health care decisions. Furthermore, this AI technology could be used for making wise decisions.

Furthermore, in February 2023, FathomX Pte Ltd. launched mammography using AI and deep learning to conduct R&D for early breast cancer diagnosis. In mammography-based breast cancer screening, the company's proprietary AI technology makes it possible to detect signs of cancerous tissue on X-ray images more quickly and accurately.

Furthermore, the prevalence of breast cancer, the need for early diagnosis, and product approvals are a few factors that drive the market in the forthcoming period.

False positive results

False-positive results are more common in women who are younger, have dense breasts, have had breast biopsies, have breast cancer in the family, or are taking estrogen. About half of the women getting annual mammograms over a 10-year period will have a false-positive finding at some point. Past history reduces their odds of a false-positive finding by about half.

Segment Analysis

The global breast cancer diagnostics is segmented based on cancer type, test type, spread, stage, end user, and region.

Early detection is crucial in improving breast cancer treatment. Innovations in screening methods have played a pivotal role in detecting breast cancer at its earliest stages. Digital mammography and tomosynthesis have replaced traditional film mammography, providing more precise and detailed images. Unlike conventional mammography, digital mammography and contrast-enhanced mammography offer better diagnosis and, thus, better treatment.

For instance, in January 2023, Bayer's iodine-based contrast agent Ultravist-300, -370 received the green light for indication extension for contrast-enhanced mammography (CEM) in a European Workshare Procedure. CEM is an emerging modality combining digital mammography with the administration of a contrast agent. Strategically expands Bayer's portfolio in breast imaging, including contrast agents and injectors. These factors are likely to increase the mammography segment in the forecast period.

Geographical Analysis

North America dominated the breast cancer diagnostics market in 2022. It is estimated to hold the largest market size over the forecast period (2022-2029) owing to rising breast cancer cases and increasing technological advancements in cancer diagnosis. For instance, as per the statistics from Breastcancer.org, as of January 2022, over 3.8 million women with a history of breast cancer in the U.S., and about 1 in 8 U.S. women (about 13%) in their lifetime would develop invasive breast cancer.

In 2022, around 287,850 new cases of invasive breast cancer were diagnosed in U.S. women, also 51,400 new cases of non-invasive (in situ) breast cancer. In 2022 about 2,710 new cases of invasive breast cancer were detected in men. In 2022, over about 43,250 women in the U.S. died from breast cancer. In addition, increasing development by manufacturers in breast cancer diagnostics is driving the market growth in this region.

COVID-19 Impact Analysis

COVID-19 has negatively impacted the global market during the outbreak since, to prevent the COVID-19 infection, various restrictions and regulations were employed, making it difficult for people to perform mammography and other breast cancer diagnostic tests affecting the market. Furthermore, a retrospective study of cases diagnosed by a reference service in the public health system of Campinas, SP, Brazil, concluded that amid the COVID-19 pandemic, breast cancer diagnoses declined. Moreover, the cases detected indicated a worsened prognosis as early detection was not performed.

Many healthcare facilities postponed non-urgent procedures and screenings, which affected the number of women getting regular tests. Additionally, fears of contracting the virus in healthcare settings and mobility restrictions further reduced screening rates. Due to these above factors, the market has seen a decline rate during the pandemic period.

By Cancer Type

  • Invasive lobular breast cancer
  • Ductal carcinoma in situ (DCIS)
  • Triple-negative breast cancer
  • Inflammatory breast cancer
  • Others

By Test Type

  • Clinical Breast Exam
  • Imaging Tests
    • Mammogram
    • MRI
    • Ultrasound
    • PET
    • Others
  • Blood Tests
  • Biopsies
    • Excisional biopsy
    • Incisional biopsy
    • Core biopsy
    • Fine-needle aspiration (FNA) biopsy
    • Others
  • Others

By Spread

  • Local
  • Regional
  • Distant

By Stage

  • I
  • II
  • III
  • IV

By End User

  • Hospitals and Clinics
  • Cancer Diagnostic Centers
  • Cancer Research Institutes
  • Medical Research Centers and Institutes
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the breast cancer diagnostics market include: Siemens Healthineers AG, Kheiron Medical Technologies, Bio-Rad Laboratories, Hologic, Inc., Quest Diagnostics Incorporated, FUJIFILM Holdings Corporation, GE Healthcare, Illumina, Inc., Metaltronica SpA, and Carestream Health among others.

Key Developments

  • In May 2022, the U.S. Department of Health and Human Services (HHS), declared the availability of US$ 5 million for community health centers, funded by HHS's Health Resources and Services Administration, to increase equitable access to life-saving breast cancer screenings.
  • In March 2022, Niramai received US FDA clearance for their first medical device, SMILE-100 System (breast thermography).

Why Purchase the Report?

  • To visualize the global breast cancer diagnostics segmentation based on cancer type, test type, spread, stage, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of breast cancer diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global breast cancer diagnostics market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Test Type
  • 3.3. Snippet by Spread
  • 3.4. Snippet by Stage
  • 3.5. Snippet by End User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancements in Diagnostic Technologies
    • 4.1.2. Restraints
      • 4.1.2.1. False Positive Results
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Epidemiology
  • 5.6. Number of Breast Cancer Tests Conducted in US, EU5, Japan, China and India 2022-2030
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type
  • 7.2. Invasive lobular breast cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Ductal carcinoma in situ (DCIS)
  • 7.4. Triple-negative breast cancer
  • 7.5. Inflammatory breast cancer
  • 7.6. Others

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type
  • 8.2. Clinical Breast Exam*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Imaging Tests
      • 8.3.1.1. MRI
      • 8.3.1.2. Ultrasound
      • 8.3.1.3. PET
      • 8.3.1.4. Others
  • 8.4. Blood Tests
  • 8.5. Biopsies
      • 8.5.1.1. Excisional biopsy
      • 8.5.1.2. Incisional biopsy
      • 8.5.1.3. Core biopsy
      • 8.5.1.4. Fine-needle aspiration (FNA) biopsy
      • 8.5.1.5. Others
  • 8.6. Others

9. By Spread

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 9.1.2. Market Attractiveness Index, By Spread
  • 9.2. Local*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Regional
  • 9.4. Distant

10. By Stage

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 10.1.2. Market Attractiveness Index, By Stage
  • 10.2. Stage I*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Stage II
  • 10.4. Stage III
  • 10.5. Stage IV

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User
  • 11.2. Hospitals and Clinics*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Cancer Diagnostic Centers
  • 11.4. Cancer Research Institutes
  • 11.5. Medical Research Centers and Institutes
  • 11.6. Ambulatory Surgical Centers
  • 11.7. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. UK
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Siemens Healthineers AG
    • 14.1.1. Company Overview
    • 14.1.2. Product Type Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Kheiron Medical Technologies
  • 14.3. Bio-Rad Laboratories
  • 14.4. Hologic, Inc.
  • 14.5. Quest Diagnostics Incorporated
  • 14.6. FUJIFILM Holdings Corporation
  • 14.7. GE Healthcare
  • 14.8. Illumina, Inc.
  • 14.9. Metaltronica SpA
  • 14.10. Carestream Health

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us